Literature DB >> 32075416

HuR (Human Antigen R) Regulates the Contraction of Vascular Smooth Muscle and Maintains Blood Pressure.

Shanshan Liu1, Xiuxin Jiang2, Hanlin Lu1, Mengdan Xing3, Yanning Qiao3, Cheng Zhang1, Wencheng Zhang1.   

Abstract

OBJECTIVE: HuR (human antigen R)-an RNA-binding protein-is involved in regulating mRNA stability by binding adenylate-uridylate-rich elements. This study explores the role of HuR in the regulation of smooth muscle contraction and blood pressure. Approach and
Results: Vascular HuRSMKO (smooth muscle-specific HuR knockout) mice were generated by crossbreeding HuRflox/flox mice with α-SMA (α-smooth muscle actin)-Cre mice. As compared with CTR (control) mice, HuRSMKO mice showed hypertension and cardiac hypertrophy. HuR levels were decreased in aortas from hypertensive patients and SHRs (spontaneously hypertensive rats), and overexpression of HuR could lower the blood pressure of SHRs. Contractile response to vasoconstrictors was increased in mesenteric artery segments isolated from HuRSMKO mice. The functional abnormalities in HuRSMKO mice were attributed to decreased mRNA and protein levels of RGS (regulator of G-protein signaling) protein(s) RGS2, RGS4, and RGS5, which resulted in increased intracellular calcium increase. Consistently, the degree of intracellular calcium ion increase in HuR-deficient smooth muscle cells was reduced by overexpression of RGS2, RGS4, or RGS5. Finally, administration of RGS2 and RGS5 reversed the elevated blood pressure in HuRSMKO mice.
CONCLUSIONS: Our findings indicate that HuR regulates vascular smooth muscle contraction and maintains blood pressure by modulating RGS expression.

Entities:  

Keywords:  blood pressure; humans; hypertension; muscle, smooth, vascular; rats

Year:  2020        PMID: 32075416     DOI: 10.1161/ATVBAHA.119.313897

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

Review 1.  Drug delivery approaches for HuR-targeted therapy for lung cancer.

Authors:  Rajeswari Raguraman; Santny Shanmugarama; Meghna Mehta; Jo Elle Peterson; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-11-22       Impact factor: 15.470

Review 2.  Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease.

Authors:  Donato Santovito; Christian Weber
Journal:  Nat Rev Cardiol       Date:  2022-03-18       Impact factor: 49.421

Review 3.  Roles of Embryonic Lethal Abnormal Vision-Like RNA Binding Proteins in Cancer and Beyond.

Authors:  Haijian Cai; Dandan Zheng; Yizhu Yao; Lehe Yang; Xiaoying Huang; Liangxing Wang
Journal:  Front Cell Dev Biol       Date:  2022-04-06

4.  Potential of RNA-binding protein human antigen R as a driver of osteogenic differentiation in osteoporosis.

Authors:  Zelin Liu; Baitao Li; Hai Hu; Xiaodong Li; Xiaofeng Zhang
Journal:  J Orthop Surg Res       Date:  2022-04-12       Impact factor: 2.359

5.  Smooth muscle-specific HuR knockout induces defective autophagy and atherosclerosis.

Authors:  Shanshan Liu; Xiuxin Jiang; Xiuru Cui; Jingjing Wang; Shangming Liu; Hongxuan Li; Jianmin Yang; Cheng Zhang; Wencheng Zhang
Journal:  Cell Death Dis       Date:  2021-04-09       Impact factor: 8.469

6.  HuR/Cx40 downregulation causes coronary microvascular dysfunction in type 2 diabetes.

Authors:  Rui Si; Jody Tori O Cabrera; Atsumi Tsuji-Hosokawa; Rui Guo; Makiko Watanabe; Lei Gao; Yun Sok Lee; Jae-Su Moon; Brian T Scott; Jian Wang; Anthony W Ashton; Jaladanki N Rao; Jian-Ying Wang; Jason X-J Yuan; Ayako Makino
Journal:  JCI Insight       Date:  2021-11-08

Review 7.  RNA-Binding Proteins: Emerging Therapeutics for Vascular Dysfunction.

Authors:  Victoria A Cornelius; Hojjat Naderi-Meshkin; Sophia Kelaini; Andriana Margariti
Journal:  Cells       Date:  2022-08-11       Impact factor: 7.666

8.  Synergistic regulation of Rgs4 mRNA by HuR and miR-26/RISC in neurons.

Authors:  Janina Ehses; Sandra M Fernández-Moya; Luise Schröger; Michael A Kiebler
Journal:  RNA Biol       Date:  2020-08-11       Impact factor: 4.652

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.